Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Epstein-Barr Virus EBV infects about 95% of adults worldwide and can lead to various conditions including infectious mononucleosis, chronic fatigue syndrome, and certain malignancies. Most EBV infections do not show symptoms due to effective immune responses. This study aims to evaluate the effects of two drugs, 2LEBV4 and 2LXFS4, compared to placebo in reducing fatigue and other symptoms associated with EBV infection. Participants will take one capsule daily of either 2LEBV4, 2LXFS4, or placebo for six continuous months. The capsules are taken sequentially according to their number on the blister pack. This treatment schedule is the same for both drugs and placebo, ensuring a consistent dosing routine during the study period. Throughout the six months, participants will be monitored for fatigue levels using the Multidimensional Fatigue Inventory-20 questionnaire and other EBV-related symptoms. Researchers will compare symptom changes and immune cell markers between treatment and placebo groups. Safety will be assessed by recording any adverse events. The studys total duration allows for comprehensive evaluation of treatment effects on EBV symptoms.